profit from every $100 of sales.
$0$100
RedHill Biopharma
$0.38-1.60% today
-65.0% in 1 year
1-year low $0.371-year high $1.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What RedHill Biopharma sold, what it kept, and what it did with the cash.
Sales went from $61.8 million in 2022 to $286,000 in 2025, with -$429,000 of profit last year.
SalesProfit
RedHill Biopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| RedHill Biopharma | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads RedHill Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 62 | 0 | 0 | 0 | |
| 28 | 3 | 5 | – | |
| -43 | -10 | -6 | -8 | |
| -22 | -16 | 1 | -8 | |
| -72 | 24 | -8 | -0 | |
| -1,200.00 | 100.00 | 0.00 | – | |
| 46.1% | – | – | – | |
| -69.3% | – | – | -2,765.4% | |
| -116.0% | – | – | -150.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 159 | 23 | 18 | 25 |
| Cash | 20 | 6 | 5 | 4 |
| Total debt | 123 | 1 | 0 | 1 |
| Total liabilities | 207 | 21 | 23 | 21 |
| -48 | 2 | -5 | 4 | |
| 0 | 0 | 1 | – | |
| -32.3% | -449.2% | – | -119.3% | |
| 148.1% | 1,155.9% | 176.6% | -10.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -36 | -9 | -10 | |
| 0 | 0 | 0 | 0 | |
| -29 | -36 | -9 | -10 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 2 | 1 | 0 |
Valuation
- –
- –
- –
- 0.4×
- 11.7×
- –
- –
- -289.7%
- -12.9%
- 0.0%
Profitability
- 63.3%
- -2,765.4%
- -150.0%
- -89.3%
- -118.5%
- 144.6%
- 291.1%
- -26.5%
- -121.8%
- 21.0%
Growth
- −83.3%
- –
- −3.0%
- –
- +141.4%
Financial health
- -0.4×
- 0.25
- 4.2%
- -7.3×
- 0.34
- 0.34
- 0.27
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 886
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Sep 5, 2025 | -1.15 | – | – |
| Oct 3, 2024 | 900.00 | – | – |
| Aug 29, 2024 | -200.00 | -30.00 | −566.7% |
| Feb 12, 2024 | -0.20 | -0.03 | −566.7% |
| Jun 30, 2023 | 4.83 | – | – |
| Jun 12, 2023 | 146.75 | – | – |
| Mar 27, 2023 | 1.07 | – | – |
| Nov 7, 2022 | -2.00 | -0.30 | −566.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
54No pass
Philip Fisher
72Pass
Peter Lynch
48No pass
Joel Greenblatt
2No pass
Charlie Munger
60Pass
Terry Smith
57No pass
Questions about RedHill Biopharma
Is RedHill Biopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the RedHill Biopharma AI analysis
What does RedHill Biopharma do?
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. It is in Drug Manufacturers - Specialty & Generic.
Does RedHill Biopharma pay a dividend?
No. RedHill Biopharma does not pay a dividend at the moment.
Is RedHill Biopharma stock halal?
No. RedHill Biopharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 119% of its market value, at or above the 33% limit. How we check
How has RedHill Biopharma stock done over the past year?
Down 65.0% over the past twelve months, to $0.38. It traded between $0.37 and $1.40 and is 73.2% below its high.
Who are RedHill Biopharma's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with RedHill Biopharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.